NEW YORK (GenomeWeb News) – Drug developer Covance and Rules-Based Medicine have struck a biomarker alliance and services agreement, Covance said today.

Under the pact, RBM will serve as Covance's exclusive third-party provider of multiplexed biomarker testing services, and Covance will serve as RBM's exclusive referral source for lab testing services.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: genomic analysis of high-grade serous ovarian cancer, and more.

The new Riken president outlines some of his plans for the institute.

The Guardian discusses whether big science projects are worth the loss of resources available for other scientific pursuits.

An NEJM update from the ClinVar team highlights the difficulties of interpreting genetic variants.